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Abstract
Background: Multi-drug resistance to chemotherapeutic agents is a major cause of treatment failure in breast
cancer. In this study, we investigated the effects of emodin on reversing the multi-drug resistance, examined the
ERCC1 protein expression in breast cancer cell line, and explored the relationship between reversal of multi-drug
resistance and ERCC1 protein expression.
Methods: MTT assay was conducted to test the cytotoxicity of adriamycin and cisplatin to MCF-7/Adr cells with
and without emodin pretreatment, and Western blot was performed to examine the ERCC1 protein expression.
Results: MCF-7/Adr cells had 21-fold and 11-fold baseline resistances to adriamycin and cisplatin, respectively.
When emodin was added to the cell culture at the concentration of 10 μg/ml, the drug resistance was reduced
from 21 folds to 2.86 folds for adriamycin, and from 11 folds to 1.79 folds for cisplatin. MCF-7/Adr cells treated with
two concentrations (10μg/mL and 20μg/mL) of emodin, after 2, 4, 6, 10 days, the trend of ERCC1 expression was
gradually decreased and the reduction was more obvious comparatively at the concentration of 20μg/mL.
Conclusions: Emodin could reverse the multi-drug resistance in MCF-7/Adr cells and down-regulate ERCC1 protein
expression.
Background
Excision repair cross complementation group 1 (ERCC1)
protein encoded by ERCC1 gene is a key player in nucleo-
tide excision repair (NER), and our previous work and
others have demonstrated that this protein is also
expressed in breast cancer [1,2]. The NER system repre-
sented by ERCC1 is extensively involved in human cell
DNA repair after damage, but over-expression of ERCC1
can lead to multi-drug resistance to chemotherapy in can-
cer treatment [3,4].
In recent years, the expression of ERCC1 was exten-
sively studied in endometrial cancer [5], ovarian cancer
[6], non-small cell lung cancer [7-9], nasopharyngeal can-
cer [10] and thymic cancer [11]. It was deemed to predict
response to anti-cancer treatment and possibly have a
prognostic role. According to the latest systematic review
of predictive value of multidrug resistance-associated
proteins (MDR1, MRP1, MRP2 and MVP), topoisome-
rase II and ERCC1, ERCC1 was a promising predictive
marker for survival in some patients [12]. However, the
study of ERCC1 in breast cancer is limited. Kim [13]
found that ERCC1 expression is low in triple-negative
breast cancer subtypes, but the relationship with survival
is still unknown. ERCC1 might have its roles in DNA
repair systems in breast cancer, but its contribution to
drug resistance remains unclear.
Emodin (EMD) is a natural anthraquinone compound
extracted from the rhizome of rhubarb. The traditional
Chinese medicinal herb was widely used for treatment of
various ailments and the anti-cancer activity of EMD was
demonstrated in some studies [14-16]. The ability to
reverse the multi-drug resistance to cancer chemothera-
peutic agents was also shown in previous pharmacologi-
cal studies [17,18]. In this in vitro study, multi-drug
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resistant breast cancer cell line MCF-7/Adr was exposed
to different levels of EMD. Drug sensitivity and ERCC1
expression were studied, so as to explore the role of
ERCC1 in breast cancer multi-drug resistance and the
effect of EMD on reversing such resistance.
Methods
Drugs and reagents
Adriamycin (ADM, Haizheng Pharmaceuticals Co., Ltd,
Zhejiang, China.), cisplation (DDP, Nanjing Pharmaceu-
ticals Co., Ltd, Jiangsu, China), Emodin (EMD, China
National Institute for the Control of Pharmaceutical and
Biological Products, Beijing China), cell culture medium
RPMI-1640 (GIBCO,USA), methyl thiazolyl tetrazolium
(MTT) assay kit (Sigma,USA), mouse anti-human
ERCC1 monoclonal antibody (Santa Cruz,USA), horse-
radish peroxidase-labeled goat anti-mouse secondary
antibody (Sigma,USA) were all commercially obtained.
ADM and EMD were reconstituted with sterile injection
water to make 2 mg/ml and 20 mg/ml stock solutions,
respectively; and DDP was reconstituted with normal
saline solution to make 5 mg/dl stock solution. All the
stock solutions were divided in appropriate aliquots and
kept in 4°C refrigerator. Application solutions were
made immediately before use by adding culture
medium.
Cell lines
Multi-drug resistant breast cancer cell line MCF-7/Adr
and its drug sensitive parent cell line MCF-7 were
obtained from Guangzhou DaHui Biotech Co., Ltd. China.
The cells were cultured in RPMI-1640 medium supple-
mented with 10% fetal bovine serum, penicillin 100 U/ml
and streptomycin 100 μg/m1, in 5% CO2, saturated
humidity, 37°C incubator. The cells show adherent growth.
In vitro study was conducted when the cells reach loga-
rithmic growth phase.
MTT assay
Cells at logarithmic growth phase were seeded on 96-well
culture plates, with 6×103 cells in each well. After
24 hours of culture, the cells were evenly attached to the
bottom of the plate. ADM, DDP and EMD of 5 concen-
tration gradients were added. After 72 hours, the medium
was removed, 100 μl of MTT reagent (5 mg/ml) was
added to each well, and the plate was cultured for
another 4 hours. Then the MTT solution was removed,
200 μl of dimethyl sulphoxide (DMSO) was added. The
plate was shaken for 15 minutes to fully dissolve the
MTT. Absorbance in each well was determined at 490
nm with enzyme-linked immunoassay detector. Cell via-
bility was determined according to the follow equation:
Cell survival rate = (absorbance in the drug test group/
absorbance in control group)×100%.
Calculation and statistical analysis
The 50% lethal concentration (IC50) was calculated
according to Reed-Muench formula and expressed as
mean ± SD. The drug resistance = (IC50 of MCF-7/Adr) ÷
(IC50 of MCF-7). Drug resistance reversal = (IC50 of MCF-
7/Adr cultured without EMD) ÷ (IC50 of MCF-7/Adr
cultured with EMD).
ERCC1 expression by Western blotting
MCF-7 and MCF-7/Adr cells at logarithmic growth phase
were seeded into 6-well plate with 1.2×104 cells in each
well. MCF-7 cells in the first well were used as negative
control. MCF-7/Adr cells in the second well were used as
blank control. MCF-7/Adr cells in the other 4 wells were
exposed to 10 μg/ml and 20 μg/ml of EMD. After cell cul-
ture for 2, 4, 6 and 10 days, the cells were harvested, and
total cell protein was extracted after cell-lysis. The cell
protein was subjected to sodium dodecyl sulphate polya-
crylamide gel electrophoresis (SDS-PAGE). The separated
proteins were transferred to nitrocellulose membrane.
After blocking in 5% skim milk for 1.5 hours, the mem-
brane was incubated with mouse anti-human ERCC1
monoclonal antibody overnight, and then horseradish per-
oxidase-labeled goat anti-mouse secondary antibody for
2 hours. After washing, the film was developed in dark-
room per protocol.
Results
When MCF-7 and MCF-7/Adr cells were exposed to
ADM gradient solutions, the IC50 of MCF-7/Adr was 21
times higher than MCF-7 (8.75 ± 0.39 μg/ml vs. 0.41 ±
0.11 μg/ml, P < 0.01) (Figure 1). When MCF-7 and
MCF-7/Adr cells were exposed to DDP gradient solu-
tions, the IC50 of MCF-7/Adr was 11 times higher than
MCF-7 (6.34 ± 0.32 μg/ml vs. 0.56 ± 0.13 μg/ml,
P<0.01) (Figure 2). After exposure to EMD at various
concentrations, the IC50 was 100 ± 0.35 μg/ml for
Figure 1 The survival rate of MCF-7 and MCF-7/Adr cells
treated with ADM for 72 hours Abbreviation: ADM: Adriamycin.
Data shown are mean ± SD from quadruplicate determinations. The
experiment was performed three times with similar results.
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MCF-7 and 79 ± 0.28 μg/ml for MCF-7/Adr (P > 0.05)
(Figure 3).
For MCF-7/Adr cells, the ADM IC50 was reduced
from 8.75 ± 0.39 μg/ml without EMD treatment to 3.06
± 0.26 μg/ml after treatment with 10 μg/ml EMD (P <
0.01). EMD had a 2.86-fold reversal of ADM IC50 for
MCF-7/Adr cells (Figure 4). For MCF-7/Adr cells, the
DDP IC50 was reduced from 6.34 ± 0.32 μg/ml without
EMD treatment to 3.54 ± 0.28 μg/ml after treatment
with 10 μg/ml EMD (P < 0.05). EMD had a 1.79-fold
reversal of ADM IC50 for MCF-7/Adr cells (Figure 5).
However, the change in IC50 of both ADM and DDP
was not statistically significant after treatment with
EMD.
The baseline ERCC1 expression was higher in MCF-7/
Adr cells than MCF-7 cells. When MCF-7/Adr cells
were treated with EMD treatment at 10 μg/ml for 2, 4,
6 and 10 days, ERCC1 expression progressively
decreased. Significantly greater inhibition of ERCC1
expression was evident when the cells were exposed to
20 μg/ml of EMD for 2, 4, 6 and 10 days. At each time
point, EMD at 20 μg/ml shows a higher inhibitiory
effect (Figure 6).
Baseline ERCC1 expression was lower in MCF-7 (nega-
tive control, Lane 1) than in MCF-7/Adr (blank control,
Lane 2). When MCF-7/Adr cells were exposed to EMD
(10μg/ml) for 2 (Lane 3), 5 (Lane 5), 6 (Lane 7) and 10
(Lane 9) days, ERCC1 expression was progressively inhib-
ited. When MCF-7/Adr cells were exposed to 20 μg/ml of
EMD, significantly greater inhibition was also observed at
each time point (Lanes 4, 6, 8 and 10).
Discussion
Multi-drug resistance to chemotherapeutic agents is a
major cause of treatment failure in breast cancer,
because chemotherapy plays ever increasing role in the
systemic treatment modalities of breast cancer both in
neoadjuvant and adjuvant chemotherapy [19,20]. For
patients who cannot obtain clinical remission during
adjuvant chemotherapy and those with recurrence and
metastasis after initial treatment, reversal of multi-drug
resistance is of crucial importance for improving clinical
outcome [21,22]. After resection of the primary tumor,
there is no validated clinical parameter to predict the
sensitivity to chemotherapy. Therefore, it is essential to
explore the molecular mechanisms of multi-drug resis-
tance and the reversal strategy are very important in
breast cancer treatment [23-26].One of the mechanisms
of tumor resistance to cisplatin is increased NER
Figure 2 The survival rate of MCF-7 and MCF-7/Adr cells
treated with DDP for 72 hours Abbreviation: DDP: Cisplatin. Data
shown are mean ± SD from quadruplicate determinations. The
experiment was performed three times with similar results
Figure 3 The survival rate of MCF-7 and MCF-7/Adr cells
treated with emodin for 72 hours Data shown are mean ± SD
from quadruplicate determinations. The experiment was performed
three times with similar results.
Figure 4 The IC50 of ADM with and without emodin for MCF-
F/Adr cells ADM: Adriamycin
Figure 5 The IC50 of DDP with and without emodin for MCF-7/
Adr cells DDP: Cisplatin
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activity, in particular increased levels of ERCC1, which is
a key gene involved in NER of damaged DNA by ultra-
violet radiation or chemical agents. The 5’ incision made
by the ERCC1-XPF complex was deemed as a rate-limit-
ing step in the NER pathway, as shown by an increase in
excision activity in extracts from non-cisplatin resistant
cells after addition of purified ERCC1-XPF protein,
compared with no increase in excision activity after
addition of ERCC1-XPF to extracts from cisplatin-resis-
tant cells [27,28]. The potential use of ERCC1 mRNA
expression as a predictive marker for the effectiveness of
cisplatin-based chemotherapy is an important area of
clinical research [29].
Patients with lower DNA repair capacity are more che-
mosensitive than those who carry a proficient DNA repair
system. In early, it was shown that elevated DNA repair
capacity is associated with drug resistance in lung cancer
cell lines [30], and it was suggested that modulation of
DNA repair mechanisms, such as the incorporation of
specific DNA repair inhibitors in therapeutic regimens.
Although low expression of ERCC1 is related to carcino-
genesis, high expression could enhance the NER, leading
to rapid repair of the damaged tumor DNA after che-
motherapy, a plausible mechanism of multi-drug resis-
tance in many cancers [31]. Thus, we processed a serial
studies about ERCC1 in breast cancer and look for novel
anti-cancer strategies to avoid drug resistance and improve
treatment outcomes.
EMD is a chemical compound of the anthraquinone
family mainly derived from the root of Rheum palma-
tum, a widely used herb in traditional Chinese medicine,
with a variety of anti-bacteria, anti-tumor and anti-con-
stipation properties. Studies at the cellular level have
shown that EMD affects cell proliferation by inhibiting
DNA synthesis, prolonging the cell cycle duration, and
suppressing mitosis. In our study, when the two breast
cancer cells were exposed to 0~120 μg/ml of EMD, the
IC50 was 100 ± 0.35 μg/ml for MCF-7 and 79 ±
0.28 μg/ml for MCF-7/Adr. At 20μg/ml EMD, cell viabi-
lity was over 85% for both MCF-7 and MCF-7/Adr.
Therefore, we selected 10μg/ml EMD at which no cell
growth inhibition was observed as the starting dose for
the reversal test. Our results showed that in MCF-7/Adr
cells, EMD could reduce the ADM-resistance by 2.86
folds, and the DDP resistance was reduced by 1.79 folds.
These results confirm that EMD is a highly effective
drug-resistance reversal agent with low toxicity.
High expression of NER repairing ability enhancement
is considered as one of the mechanisms of tumor drug
resistance [32,33]. In this study, two concentrations of
emodin, 20μg/mL and 10μg/mL, were used to deal with
low toxicity concentration MCF-7/Adr cell line, in 2, 4, 6
and10 days and the expression of ERCC1 protein was
examined by Western blotting. The results showed
higher levels of ERCC1 protein expression in MCF-7/Adr
cell lines than in MCF-7 ones, but after emodin treat-
ment, the ERCC1 protein levels decreased further and is
significantly time-dependent and possibly dose-depen-
dent as greater inhibitory effect was observed in the con-
centration of 20μg/ml. Given that only two concentration
were studied, it may still have a certain concentration
range to explore further the true dose-effect relationship.
Many new anti-cancer agents is being developed in
recent years, but many studies have now focused on the
reversal of chemoresistance in tumor in order to maxi-
mize the treatment capacity of existing chemotherapeu-
tic agents. Some medicinal herbs may hold great
potential in this field. This in vitro study found that
EMD can significantly reverse the multi-drug resistance
and reduce ERCC1 expression in breast cancer cells.
Further studies are warranted to explore how ERCC1
plays role in reversing drug resistance and more pre-
clinical evidence is necessary before the use emodin will
be studied in clinical trials.
Figure 6 Western blotting results Lane 1: Negative/loading control; lane 2: Blank control; lane 3, 5, 7, 9: Cells exposed to 10μg/ml EMD; lane 4,
6, 8, 10: Cells exposed to 20μg/ml EMD
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Conclusions
In this in vitro study, we noticed that ERCC1 expression
might be associated with drug resistance and that emo-
din might play a possible role of reversing drug resis-
tance. This is a preliminary finding which needs further
investigation to explore the use of emodin in breast can-
cer treatment. However, we must emphasize that with
recent advances of molecular biology, breast cancer was
categorized into many different molecular subtypes
which might possess different characteristics from carci-
nogenesis to metastasis. Therefore, the study of a single
biomarker might be further complicated. Nevertheless,
we believe further studies on ERCC1 expression in
breast cancer and emodin in facilitating the reversal of
drug resistance are warranted.
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